Alaunos Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO Alaunos Therapeutics is Dale Hogue, benoemd in Jan2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde $ 9.56K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 3.9 jaar.
Belangrijke informatie
Dale Hogue
Algemeen directeur
US$11.1k
Totale compensatie
Percentage CEO-salaris | n/a |
Dienstverband CEO | less than a year |
Eigendom CEO | 0.2% |
Management gemiddelde ambtstermijn | 3yrs |
Gemiddelde ambtstermijn bestuur | 3.9yrs |
Recente managementupdates
Recent updates
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?
Nov 10Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology
Oct 04Alaunos posts 51% tumor reduction for lung cancer therapy
Sep 21Alaunos sheds 52% ahead of data readout for T-cell therapy platform
Sep 15Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data
Aug 31Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02
Aug 15Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?
Jul 26Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?
Apr 06Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?
Dec 20Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies
Jun 19ZIOPHARM records sharpest gain in nearly four months
Jun 09Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?
May 11ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?
Mar 09We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely
Jan 15ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022
Jan 14Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients
Dec 21Activist holder wins Ziopharm Oncology board seats
Dec 17Ziopharm Oncology CFO to step down
Dec 14What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?
Nov 23Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution
Nov 20ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Ziopharm Oncology thumbs down on investor's call for board seats
Nov 02CEO
Dale Hogue (54 yo)
less than a year
Tenure
US$11,090
Compensatie
Mr. Dale Curtis Hogue, Jr. is Director of Alaunos Therapeutics, Inc. from December 29, 2023 and also serves as Interim Chief Executive Officer from January 20, 2024. Mr. Hogue has worked in various roles...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Interim CEO & Director | less than a year | US$11.09k | 0.25% $ 9.6k | |
Senior VP of Legal | 3yrs | US$701.74k | geen gegevens | |
Vice President of Finance & Principal Accounting Officer | 3.2yrs | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
47yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TCRT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Interim CEO & Director | less than a year | US$11.09k | 0.25% $ 9.6k | |
Independent Chairman of the Board | 3.9yrs | US$900.26k | 0.076% $ 2.9k | |
Chairman of Scientific Advisory Board | 4.4yrs | geen gegevens | geen gegevens | |
Independent Director | 3.9yrs | US$103.26k | 0.97% $ 37.0k | |
Member of Scientific Advisory Board | 4.2yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 4.2yrs | geen gegevens | geen gegevens | |
Independent Director | 1.7yrs | US$84.01k | 0% $ 0 | |
Independent Director | 3.8yrs | US$104.26k | 0.52% $ 19.8k | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TCRT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).